Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Q&A: Proteus Promotes Medication Adherence Using Ingestible Sensors

This article was originally published in The Gray Sheet

Executive Summary

On the heels of FDA clearance for the firm's ingestible sensor technology, Proteus Digital Health Chief Medical Officer George Savage talks to “The Gray Sheet.”

You may also be interested in...



Bringing A Digital Pill To Oncology: Proteus Partners With Health System To Prescribe Sensor-Enabled Chemotherapy

Proteus Digital Health announced a new partnership with Fairview Health Services and the University of Minnesota Health to prescribe capecitabine, a common chemotherapy drug, encapsulated with a sensor to colorectal cancer patients. Under the program, patients are prescribed the "digital capecitabine" and will be monitored remotely to see when they take their meds and for other health data. The goal is to improve patients' treatment adherence and improve outcomes.

First ‘Digital Medicine’ Approved, Slow Rollout Planned

FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.

Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road

Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.

Topics

Latest News
UsernamePublicRestriction

Register

MT031453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel